Details:
The financing will help ensure the company have the necessary resources to continue achieving its goals to advance the development of NBTXR3.
Lead Product(s): Hafnium Oxide
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase II/ Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: HSBC
Deal Size: $11.1 million Upfront Cash: Undisclosed
Deal Type: Financing June 08, 2020